GB0525461D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB0525461D0
GB0525461D0 GBGB0525461.0A GB0525461A GB0525461D0 GB 0525461 D0 GB0525461 D0 GB 0525461D0 GB 0525461 A GB0525461 A GB 0525461A GB 0525461 D0 GB0525461 D0 GB 0525461D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0525461.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Archimedes Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Development Ltd filed Critical Archimedes Development Ltd
Priority to GBGB0525461.0A priority Critical patent/GB0525461D0/en
Publication of GB0525461D0 publication Critical patent/GB0525461D0/en
Priority to JP2008545097A priority patent/JP2009519313A/ja
Priority to US12/097,163 priority patent/US8460702B2/en
Priority to CA2634006A priority patent/CA2634006C/en
Priority to PCT/GB2006/004710 priority patent/WO2007068948A2/en
Priority to EP06820546A priority patent/EP1978950A2/en
Priority to BRPI0619934-8A priority patent/BRPI0619934A2/pt
Priority to IL192091A priority patent/IL192091A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0525461.0A 2005-12-15 2005-12-15 Pharmaceutical compositions Ceased GB0525461D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0525461.0A GB0525461D0 (en) 2005-12-15 2005-12-15 Pharmaceutical compositions
JP2008545097A JP2009519313A (ja) 2005-12-15 2006-12-15 医薬組成物
US12/097,163 US8460702B2 (en) 2005-12-15 2006-12-15 Pharmaceutical compositions
CA2634006A CA2634006C (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine
PCT/GB2006/004710 WO2007068948A2 (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising in particular thyroid hormones
EP06820546A EP1978950A2 (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comrising in particular thyroid hormones
BRPI0619934-8A BRPI0619934A2 (pt) 2005-12-15 2006-12-15 composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição
IL192091A IL192091A (en) 2005-12-15 2008-06-12 Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525461.0A GB0525461D0 (en) 2005-12-15 2005-12-15 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB0525461D0 true GB0525461D0 (en) 2006-01-25

Family

ID=35736122

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0525461.0A Ceased GB0525461D0 (en) 2005-12-15 2005-12-15 Pharmaceutical compositions

Country Status (8)

Country Link
US (1) US8460702B2 (enExample)
EP (1) EP1978950A2 (enExample)
JP (1) JP2009519313A (enExample)
BR (1) BRPI0619934A2 (enExample)
CA (1) CA2634006C (enExample)
GB (1) GB0525461D0 (enExample)
IL (1) IL192091A (enExample)
WO (1) WO2007068948A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
EP3125873B1 (en) 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
CN120154576A (zh) 2018-08-31 2025-06-17 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
EP0550108B1 (en) 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
CA2318128C (en) 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
WO1999063969A1 (en) * 1998-06-08 1999-12-16 Groenewoud Pieter J Stabilized thyroxine medications
KR100603900B1 (ko) * 1998-10-01 2006-07-25 노파르티스 아게 신규의 서방성 경구 제제
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
EP1267879A2 (en) 2000-03-30 2003-01-02 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
IL152179A (en) * 2000-04-10 2009-06-15 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
AU2003231919A1 (en) 2002-03-14 2003-09-22 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
AU2006230557A1 (en) 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Also Published As

Publication number Publication date
IL192091A (en) 2012-04-30
CA2634006A1 (en) 2007-06-21
BRPI0619934A2 (pt) 2011-10-25
EP1978950A2 (en) 2008-10-15
WO2007068948A2 (en) 2007-06-21
US8460702B2 (en) 2013-06-11
CA2634006C (en) 2013-07-30
IL192091A0 (en) 2008-12-29
US20090130202A1 (en) 2009-05-21
JP2009519313A (ja) 2009-05-14
WO2007068948A3 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
GB0513692D0 (en) Novel pharmaceutical compositions
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL188352A0 (en) Pharmaceutical compositions
IL186336A0 (en) Pharmaceutical composition
ZA200804103B (en) Pharmaceutical compositions
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
IL192091A0 (en) Pharmaceutical compositions
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0522045D0 (en) Pharmaceutical compositions
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0407351D0 (en) Pharmaceutical compositions
GB0400971D0 (en) Pharmaceutical compositions
ZA200803566B (en) Pharmaceutical compositions
GB0514259D0 (en) Pharmaceutical compositions
GB0502792D0 (en) Pharmaceutical compositions
GB0411502D0 (en) Pharmaceutical compositions
GB0515306D0 (en) Pharmaceutical compositions
GB0525269D0 (en) Pharmaceutical compositions
GB0512202D0 (en) Novel pharmaceutical compositions
GB0513693D0 (en) Novel pharmaceutical compositions
GB0505693D0 (en) Novel pharmaceutical compositions
GB0513440D0 (en) Novel pharmaceutical compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)